Goldman Sachs’s Evelo Biosciences, Inc. Common Stock EVLO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q2
– Sell
-1,285
Closed -$4.64K – 6211
2023
Q1
$4.64K Sell
1,285
-282
-18% -$4.35K ﹤0.01% 5799
2022
Q4
$50.5K Sell
1,567
-136
-8% -$5.38K ﹤0.01% 5597
2022
Q3
$71K Sell
1,703
-399
-19% -$18.2K ﹤0.01% 5758
2022
Q2
$89K Sell
2,102
-596
-22% -$27.6K ﹤0.01% 5898
2022
Q1
$183K Buy
2,698
+205
+8% +$17.1K ﹤0.01% 5920
2021
Q4
$302K Buy
2,493
+568
+30% +$95.9K ﹤0.01% 5665
2021
Q3
$271K Buy
1,925
+586
+44% +$116K ﹤0.01% 5563
2021
Q2
$368K Buy
1,339
+636
+90% +$160K ﹤0.01% 5396
2021
Q1
$150K Buy
703
+142
+25% +$39.2K ﹤0.01% 5741
2020
Q4
$136K Buy
561
+51
+10% +$6.31K ﹤0.01% 5229
2020
Q3
$54K Buy
+510
New +$46.5K ﹤0.01% 5183
2019
Q3
– Sell
-13,482
Closed -$2.42M – 5443
2019
Q2
$2.42M Sell
13,482
-9
-0.1% -$1.46K ﹤0.01% 3404
2019
Q1
$2.16M Sell
13,491
-786
-6% -$156K ﹤0.01% 3597
2018
Q4
$3.71M Sell
14,277
-1,421
-9% -$286K ﹤0.01% 3126
2018
Q3
$3.82M Sell
15,698
-1,140
-7% -$298K ﹤0.01% 3177
2018
Q2
$3.97M Buy
+16,838
New +$4.91M ﹤0.01% 3119

Other funds holding EVLO

Goldman Sachs's EVLO Position: Q2 2023 in Review

Goldman Sachs sold out of Evelo Biosciences, Inc. Common Stock (EVLO) in Q2 2023, closing a stake of 1,285 shares — an estimated $4.64K sold.

Goldman Sachs first reported a position in EVLO in Q2 2018 and held it in 16 quarters. The position peaked at $3.97M in Q2 2018. 25 funds tracked by Wall St. Rank hold EVLO as of Q2 2023.

  • Goldman Sachs reported no remaining Evelo Biosciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • Goldman Sachs sold 1,285 Evelo Biosciences, Inc. Common Stock shares in Q2 2023, an estimated $4.64K.
  • Goldman Sachs first reported a position in Evelo Biosciences, Inc. Common Stock in Q2 2018 and held it in 16 quarters.
  • Goldman Sachs's Evelo Biosciences, Inc. Common Stock position peaked at $3.97M in Q2 2018.
  • 25 funds tracked by Wall St. Rank held Evelo Biosciences, Inc. Common Stock as of Q2 2023.

Based on Goldman Sachs's 13F filing for Q2 2023, filed 15 Aug 2023.